German biopharmaceutical company CureVac saw its shares drop 50% in extended trading on Wednesday after the company released preliminary efficacy results about its COVID-19 vaccine candidate. Data showed that the Covid vaccine demonstrated an interim efficacy of 47% against Covid-19 disease “of any severity.” The late-stage clinical trial found high prevalence of virus variants. The … Continue reading “CureVac Shares Collapse as Preliminary Data Shows Covid Vaccine is Just 47% Effective”
